FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 22, 2007
filing date -
Oct 20, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully